Cue Biopharma (CUE) Equity Ratio (2017 - 2025)

Cue Biopharma has disclosed Equity Ratio across 9 years of filings, most recently posting 0.63 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.63, up 15.19% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.63 (up 15.19% YoY), and the FY2025 annual result was 0.63, up 15.19% from the prior year.
• Equity Ratio came in at 0.63 for Q4 2025 at Cue Biopharma, up from 0.42 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.81 in Q2 2021 to a low of 0.3 in Q1 2025.
• The 5-year median for Equity Ratio is 0.63 (2023), against an average of 0.62.
• Peak annual rise in Equity Ratio reached 15.19% in 2025, while the deepest fall reached 46.89% in 2025.
• Cue Biopharma's Equity Ratio stood at 0.79 in 2021, then retreated by 8.37% to 0.72 in 2022, then slipped by 16.24% to 0.6 in 2023, then fell by 9.81% to 0.54 in 2024, then grew by 15.19% to 0.63 in 2025.
• The last three Equity Ratio figures came in at 0.63 (Q4 2025), 0.42 (Q3 2025), and 0.45 (Q2 2025), per Business Quant data.